Methods to Detect Liver Fibrosis

Cincinnati Children's Hospital Medical Center logo

Cincinnati Children's Hospital Medical Center

Status

Terminated

Conditions

Liver Fibroses
Hepatic Steatosis

Treatments

Device: MRI

Study type

Interventional

Funder types

Other

Identifiers

NCT03027700
CIN001- Liver Fibrosis

Details and patient eligibility

About

The goal of this study is to learn more about liver fibrosis and methods to detect it. We will evaluate and compare multiple MRI based measures of liver fibrosis in subjects with and without liver disease.

Full description

While liver biopsy is still considered the gold standard for diagnosing and assessing the presence and degree of liver fibrosis and inflammation, it has disadvantages including the potential for sampling error and risk of complications, including life-threatening bleeding. New imaging modalities such as MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer allow rapid, non-invasive evaluation of liver parenchymal characteristics and may be able to detect and quantify parenchymal fibrosis alleviating the need for biopsy. To date, the quantitative performance of these different techniques has not been extensively studied. This study is a single-center trial of non-invasive MR imaging techniques aimed at detecting and measuring liver fibrosis. Once optimized, these technologies may later be deployed in hypothesis driven research studies and/or routine clinical exams in the pediatric population here at CCHMC and/or as part of a multi-center study with specific IRB approval for that project. To assess the relative performance of each technique, correlation across techniques, and reproducibility across the range of fibrosis, 32 subjects will be enrolled in this preliminary study sub-divided into 4 groups (Group 1: Healthy/ Normal controls; Group 2: F1/F2 fibrosis as determined by prior biopsy (low grade fibrosis group); Group 3: F3/F4 fibrosis as determined by prior biopsy (high grade fibrosis group), Group 4: Hepatic steatosis with fibrosis (NAFLD group)). 8 healthy subjects without known or suspected liver disease will be enrolled as normal controls. 8 subjects each with known fibrosis based on liver biopsy within the last 6 months will be enrolled in Group 2 and Group 3 (total = 16). 8 subjects with known hepatic steatosis and liver fibrosis based on liver biopsy within the last 6 months will be enrolled in Group 4.

Enrollment

6 patients

Sex

All

Ages

8 to 21 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Group 1:

  • Healthy subjects with no known or suspected liver disease
  • Age 8 - 21 years

Groups 2 and 3:

  • Biopsy confirmed liver fibrosis (F1/F2 Group 2, F3/F4 Group 3)
  • Age 8 - 21 years

Group 4:

  • Biopsy confirmed hepatic steatosis AND biopsy confirmed liver fibrosis (any stage)
  • Age 8 - 21 years

Exclusion Criteria

All subjects:

  • Subjects <8 years of age and >21 years of age.
  • BMI > 35 kg/m2
  • Subjects deemed to possibly require sedation to undergo MR imaging
  • Inability to lie still for 90 minutes
  • Routine exclusions to MRI - e.g., implanted hardware
  • Pregnancy (verbal pregnancy screens - per standard practice in Radiology - will be administered to all female participants of child-bearing age at the time of enrollment and again immediately prior to imaging)
  • Prior history of liver transplantation

Group 1

  • ALT ≥30 U/L
  • Clinical history or lab/biopsy results suggestive of the presence of liver disease including: steatosis, fibrosis, inflammation, tumor, etc.

Group 2 and 3

  • Diagnosis of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis
  • Biopsy >6 months prior to research MRI examination
  • Initiation of any medications (e.g. steroids, immunosuppressants, antivirals) or procedures (e.g. Kasai portoenterostomy) to treat the liver disease during the time between liver biopsy and study visit

Group 4

  • Biopsy >6 months prior to research MRI examination
  • Hepatic fat fraction >5%
  • Substantial weight loss (>10% of weight at time of biopsy) during the time between biopsy and study visit
  • Initiation of any medications to treat NAFLD (e.g. vitamin E) during the time between biopsy and study visit

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

6 participants in 4 patient groups

Health/Normal Controls
Active Comparator group
Description:
Health/normal control subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
Treatment:
Device: MRI
F1/F2 fibrosis
Active Comparator group
Description:
Type 1 and 2 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
Treatment:
Device: MRI
F3/F4 fibrosis
Active Comparator group
Description:
Type 2 and 3 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
Treatment:
Device: MRI
Hepatic steatosis with fibrosis
Active Comparator group
Description:
Hepatic steatosis with liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
Treatment:
Device: MRI

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems